KNSA Stock Analysis: Buy, Sell, or Hold?
KNSA - Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares
$79.03
0.56 (0.71%)
â˛
5d:
+2.97%
30d:
+25.34%
90d:
+47.31%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Oct 27, 2026
Get Alerted When KNSA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: KNSA is fairly priced but lacks strong directional signals. At 17.7% expected growth, valuation appears stretched. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: KNSA is fairly priced but lacks strong directional signals. At 17.7% expected growth, valuation appears stretched. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$78.75
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$48.90
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: KNSA is currently trading at $79.03, which is considered slightly high relative to its 30-day fair value range of $65.73 to $80.11. From a valuation perspective, the stock is trading at a premium (Forward PE: 48.9) compared to its historical average (30.0). At these levels, the market is pricing in 17.7% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, KNSA is in a strong uptrend. Immediate support is located at $75.00, while resistance sits at $81.57.
Market Sentiment: KNSA scores 16/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $98.00 (+24.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, KNSA is in a strong uptrend. Immediate support is located at $75.00, while resistance sits at $81.57.
Market Sentiment: KNSA scores 16/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $98.00 (+24.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$65.73 -
$80.11
Company Quality Score
44/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
53.1%
Protect Your Profits
Holding KNSA? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Options cheap (IV 0th percentile)
- BEARISH: Weak technical setup (16/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 24.0% below Wall St target ($98.00)
- NEUTRAL: Trading at premium valuation - market expects 17.7% growth which is achievable
- WARNING: Composite score 44/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$65.73 -
$80.11
Current vs Trading Range
SLIGHTLY HIGH
Expected Move (7 Days)
Âą$4.99
(6.3%)
Support & Resistance Levels
Support Level
$75.00
Resistance Level
$81.57
Current Trend
Strong Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
48.86
Wall Street Target
$98.00
(+24.0%)
Revenue Growth (YoY)
55.4%
Earnings Growth (YoY)
30.4%
Profit Margin
9.6%
Valuation Premium vs History
+17.7% premium
PE vs Historical
48.9 vs 30.0
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+17.7%
(market-implied from PE analysis)
1-Year Target
$93.02
(+18%)
2-Year Target
$109.48
(+39%)
3-Year Target
$128.86
(+63%)
3-Yr Target (if PE normalizes)
(PE: 49â30)
PE COMPRESSION
$79.12
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 48.9, Growth: 39.7%)
$215.66
(+173%)
Base:
(SPY PE: 20.1, Growth: 39.7%)
$88.59
(+12%)
Bear:
(PE: 17.1, Growth: 39.7%)
$75.30
(-5%)
đ
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (82x PE), but valuation improves significantly next year (49x PE) as earnings recover.
Trailing PE: 81.74 | Current EPS (TTM): $0.96
Bull Case
$145.44
(+84%)
Analyst growth 68.5%, PE expands to 89.9
Base Case
$132.21
(+67%)
Market implied 68.5%, PE stable at 81.7
Bear Case
$53.36
(-33%)
Severe decline -20.0%, PE contracts to 69.5
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: August 23, 2026 9:21 PM ET
Data refreshes hourly during market hours. Next update: 10:21 PM
Data refreshes hourly during market hours. Next update: 10:21 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is KNSA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
5
Sells
Net
INSIDERS SELLING
Recent Transactions
Ross Moat
SELL
1703 shares
2026-04-09
Michael R Megna
SELL
6625 shares
2026-04-09
Barry D Quart
SELL
6901 shares
2026-04-06
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences IâĻ |
STRONG BUY
25 analysts |
$212 | 67 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$107 | 56 HOLD |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$101 | 43 HOLD |
|
UTHR
United Therapeutics CorpâĻ |
STRONG BUY
15 analysts |
$664 | 48 HOLD |
|
LQDA
Liquidia Technologies Inc |
STRONG BUY
10 analysts |
$108 | 55 HOLD |
Advanced KNSA Option Strategies
Professional options setups generated by AI based on today's KNSA price and gamma walls.
